NASDAQ:SLXP - Salix Pharmaceuticals Stock Price, Price Target & More

$172.81 0.00 (0.00 %)
(As of 04/25/2018 03:03 AM ET)
Previous Close$172.81
Today's RangeN/A
52-Week Range$86.00 - $172.98
VolumeN/A
Average Volume4.96 million shs
Market Capitalization$10.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94

About Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals logoSalix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive SLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for SLXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SLXP
CUSIP79543510
Phone+1-919-8621000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,134.34%
Return on Equity-305.24%
Return on Assets-25.83%

Miscellaneous

EmployeesN/A
Outstanding Shares64,250,000

How to Become a New Pot Stock Millionaire

Salix Pharmaceuticals (NASDAQ:SLXP) Frequently Asked Questions

What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

How were Salix Pharmaceuticals' earnings last quarter?

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced its earnings results on Monday, March, 2nd. The specialty pharmaceutical company reported ($2.61) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $2.32. The specialty pharmaceutical company earned $13 million during the quarter, compared to analysts' expectations of $187.97 million. Salix Pharmaceuticals had a negative net margin of 2,134.34% and a negative return on equity of 305.24%. During the same quarter last year, the business posted $1.06 earnings per share. View Salix Pharmaceuticals' Earnings History.

Has Salix Pharmaceuticals been receiving favorable news coverage?

News articles about SLXP stock have been trending positive on Wednesday, Accern Sentiment reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Salix Pharmaceuticals earned a daily sentiment score of 0.35 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 48.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Salix Pharmaceuticals?

Shares of SLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Salix Pharmaceuticals' stock price today?

One share of SLXP stock can currently be purchased for approximately $172.81.

How big of a company is Salix Pharmaceuticals?

Salix Pharmaceuticals has a market capitalization of $10.94 billion.

How can I contact Salix Pharmaceuticals?

Salix Pharmaceuticals' mailing address is 8510 Colonnade Center Dr, RALEIGH, NC 27615-3050, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8621000.


MarketBeat Community Rating for Salix Pharmaceuticals (SLXP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  621
MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe SLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Salix Pharmaceuticals (NASDAQ:SLXP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)

Earnings

Salix Pharmaceuticals (NASDAQ:SLXP) Earnings History and Estimates Chart

Earnings by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals (NASDAQ SLXP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2015Q414($0.29)($2.61)$187.97 million$13.00 millionViewN/AView Earnings Details
11/6/2014Q314$1.56$1.53$394.00 million$354.70 millionViewN/AView Earnings Details
8/7/2014Q214$1.69$1.59$397.06 million$382.00 millionViewListenView Earnings Details
5/8/2014Q114$0.91$1.05$372.91 million$384.00 millionViewListenView Earnings Details
2/27/2014Q413$0.93$1.06$247.29 million$257.60 millionViewListenView Earnings Details
11/7/2013Q313$0.86$0.89$239.70 million$238.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.81$0.87$226.34 million$235.40 millionViewListenView Earnings Details
5/9/2013Q1 2013$0.67$0.63$205.94 million$202.60 millionViewListenView Earnings Details
2/28/2013Q4 2012$0.78$0.81$199.41 million$198.17 millionViewN/AView Earnings Details
11/7/2012Q312$0.69$0.95$187.23 million$185.13 millionViewN/AView Earnings Details
8/8/2012$0.54$0.79ViewN/AView Earnings Details
5/7/2012$0.56$0.67ViewN/AView Earnings Details
2/27/2012Q4 2011$0.97$1.18ViewN/AView Earnings Details
11/8/2011$0.60$0.77ViewN/AView Earnings Details
8/8/2011$0.44$0.32ViewN/AView Earnings Details
5/5/2011$0.17$0.34ViewN/AView Earnings Details
2/28/2011$0.49$0.66ViewN/AView Earnings Details
11/8/2010Q3 2010($0.15)($0.05)ViewN/AView Earnings Details
8/9/2010Q2 2010$0.10$0.13ViewN/AView Earnings Details
5/10/2010Q1 2010($0.51)($0.45)ViewN/AView Earnings Details
3/9/2010Q4 2009($0.14)($0.13)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.29)($0.15)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.34)($0.32)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.37)($0.29)ViewN/AView Earnings Details
3/10/2009Q4 2008($0.11)($0.22)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.31)($0.11)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.37)($0.15)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.46)($0.50)ViewN/AView Earnings Details
3/3/2008Q4 2007$0.32$0.32ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Salix Pharmaceuticals (NASDAQ:SLXP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Salix Pharmaceuticals (NASDAQ SLXP) Insider Trading and Institutional Ownership History

Insider Trading History for Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals (NASDAQ SLXP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2015Timothy J CreechInsiderSell4,600$157.67$725,282.00View SEC Filing  
3/6/2015William P ForbesEVPSell20,000$157.96$3,159,200.00View SEC Filing  
11/12/2014William P ForbesEVPSell11,079$95.05$1,053,058.95View SEC Filing  
6/26/2014Carolyn J LoganCEOSell53,057$123.38$6,546,172.66View SEC Filing  
4/22/2014Alonzo Thomas DDirectorSell11,530$110.89$1,278,561.7079,179View SEC Filing  
1/10/2014Alonzo Thomas DDirectorSell12,050$91.83$1,106,551.5097,974View SEC Filing  
1/9/2014Adam DerbyshireCFOSell30,001$91.48$2,744,491.48179,395View SEC Filing  
1/8/2014William ForbesEVPSell8,000$90.06$720,480.0081,573View SEC Filing  
1/7/2014Rick ScruggsEVPSell8,463$88.31$747,367.5353,714View SEC Filing  
1/7/2014William KeaneDirectorSell22,500$88.31$1,986,975.0035,240View SEC Filing  
7/24/2013William P ForbesEVPSell12,000$70.93$851,160.00View SEC Filing  
4/10/2013William P ForbesEVPSell8,673$49.37$428,186.01View SEC Filing  
12/26/2012Adam C DerbyshireCFOSell60,000$41.44$2,486,400.00View SEC Filing  
11/13/2012Mark A SirgoDirectorSell3,450$40.53$139,828.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Salix Pharmaceuticals (NASDAQ SLXP) News Headlines

Source:
DateHeadline
Salix Provides Update on FDA Submission for PLENVU®*Salix Provides Update on FDA Submission for PLENVU®*
www.prnewswire.com - February 9 at 9:28 AM
Financial Analysis: Salix Pharmaceuticals (SLXP) vs. Advanced Accelerator Application (AAAP)Financial Analysis: Salix Pharmaceuticals (SLXP) vs. Advanced Accelerator Application (AAAP)
www.americanbankingnews.com - January 26 at 11:08 PM
Reviewing Salix Pharmaceuticals (SLXP) and Advanced Accelerator Application (AAAP)Reviewing Salix Pharmaceuticals (SLXP) and Advanced Accelerator Application (AAAP)
www.americanbankingnews.com - January 7 at 11:26 PM
Reviewing Salix Pharmaceuticals (SLXP) & Check Cap (CHEK)Reviewing Salix Pharmaceuticals (SLXP) & Check Cap (CHEK)
www.americanbankingnews.com - December 19 at 11:24 AM
Salix Pharmaceuticals (SLXP) versus Its Competitors Head-To-Head ContrastSalix Pharmaceuticals (SLXP) versus Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - December 3 at 4:14 PM
Critical Analysis: Eagle Pharmaceuticals (EGRX) and Salix Pharmaceuticals (SLXP)Critical Analysis: Eagle Pharmaceuticals (EGRX) and Salix Pharmaceuticals (SLXP)
www.americanbankingnews.com - December 1 at 5:12 PM
Financial Analysis: Salix Pharmaceuticals (SLXP) and Aimmune Therapeutics (AIMT)Financial Analysis: Salix Pharmaceuticals (SLXP) and Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - November 29 at 11:30 PM
Salix Pharmaceuticals (SLXP) versus Its Rivals Critical AnalysisSalix Pharmaceuticals (SLXP) versus Its Rivals Critical Analysis
www.americanbankingnews.com - November 29 at 1:14 AM
Analyzing Salix Pharmaceuticals (SLXP) and The CompetitionAnalyzing Salix Pharmaceuticals (SLXP) and The Competition
www.americanbankingnews.com - November 24 at 7:20 PM
Financial Comparison: Salix Pharmaceuticals (SLXP) & Its CompetitorsFinancial Comparison: Salix Pharmaceuticals (SLXP) & Its Competitors
www.americanbankingnews.com - November 22 at 9:42 AM
Salix Pharmaceuticals (SLXP) and Its Competitors Critical AnalysisSalix Pharmaceuticals (SLXP) and Its Competitors Critical Analysis
www.americanbankingnews.com - November 20 at 5:16 AM
Analyzing Salix Pharmaceuticals (SLXP) and Its CompetitorsAnalyzing Salix Pharmaceuticals (SLXP) and Its Competitors
www.americanbankingnews.com - November 19 at 9:26 PM
Critical Review: Salix Pharmaceuticals (SLXP) vs. Its CompetitorsCritical Review: Salix Pharmaceuticals (SLXP) vs. Its Competitors
www.americanbankingnews.com - November 19 at 7:12 AM
Salix Pharmaceuticals (SLXP) vs. Its Rivals Head to Head SurveySalix Pharmaceuticals (SLXP) vs. Its Rivals Head to Head Survey
www.americanbankingnews.com - November 18 at 9:08 PM
Salix Pharmaceuticals (SLXP) versus Its Rivals Financial SurveySalix Pharmaceuticals (SLXP) versus Its Rivals Financial Survey
www.americanbankingnews.com - November 13 at 7:30 PM
Critical Comparison: Salix Pharmaceuticals (SLXP) vs. Its CompetitorsCritical Comparison: Salix Pharmaceuticals (SLXP) vs. Its Competitors
www.americanbankingnews.com - November 5 at 7:16 PM
Financial Survey: Salix Pharmaceuticals (SLXP) & The CompetitionFinancial Survey: Salix Pharmaceuticals (SLXP) & The Competition
www.americanbankingnews.com - November 4 at 7:29 PM
Valeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) CollapseValeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) Collapse
finance.yahoo.com - October 6 at 11:03 AM
Contrasting Supernus Pharmaceuticals (SUPN) & Salix Pharmaceuticals (SLXP)Contrasting Supernus Pharmaceuticals (SUPN) & Salix Pharmaceuticals (SLXP)
www.americanbankingnews.com - September 28 at 10:48 AM
Critical Survey: Salix Pharmaceuticals (SLXP) vs. Assembly Biosciences (ASMB)Critical Survey: Salix Pharmaceuticals (SLXP) vs. Assembly Biosciences (ASMB)
www.americanbankingnews.com - September 23 at 10:28 PM
Mallinckrodt PLC (MNK) and Salix Pharmaceuticals (SLXP) Critical ReviewMallinckrodt PLC (MNK) and Salix Pharmaceuticals (SLXP) Critical Review
www.americanbankingnews.com - September 11 at 12:08 AM
Salix Pharmaceuticals (SLXP) versus AbbVie (ABBV) Head to Head SurveySalix Pharmaceuticals (SLXP) versus AbbVie (ABBV) Head to Head Survey
www.americanbankingnews.com - September 3 at 10:24 PM
Head to Head Analysis: AbbVie (ABBV) and Salix Pharmaceuticals (SLXP)Head to Head Analysis: AbbVie (ABBV) and Salix Pharmaceuticals (SLXP)
www.americanbankingnews.com - August 15 at 12:16 PM
Financial Comparison: Salix Pharmaceuticals (SLXP) versus Novan (NOVN)Financial Comparison: Salix Pharmaceuticals (SLXP) versus Novan (NOVN)
www.americanbankingnews.com - July 31 at 9:41 AM
Bill Ackman To Investors: Deeply And Profoundly Sorry For The Valeant FiascoBill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco
www.benzinga.com - March 31 at 1:09 AM
Valeant stock falls 5% after company files 10-KValeant stock falls 5% after company files 10-K
www.marketwatch.com - March 1 at 8:14 PM
[$$] Allergan Admits to Disclosure Violations During Valeant Bid[$$] Allergan Admits to Disclosure Violations During Valeant Bid
www.wsj.com - February 9 at 4:24 AM
Valeant Pharmaceuticals: We Were Wrong, Morgan Stanley SaysValeant Pharmaceuticals: We Were Wrong, Morgan Stanley Says
blogs.barrons.com - December 16 at 3:56 AM
Why Valeant is CrumblingWhy Valeant is Crumbling
us.rd.yahoo.com - December 1 at 1:11 AM
Valeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?!Valeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?!
blogs.barrons.com - November 30 at 8:09 PM
Uh Oh, Valeants Hiring. Why Thats Very Bad News.Uh Oh, Valeant's Hiring. Why That's Very Bad News.
blogs.barrons.com - November 30 at 10:42 AM
Valeants Asset Sale Clock is TickingValeant's Asset Sale Clock is Ticking
www.bloomberg.com - November 21 at 12:47 PM
Is Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime?Is Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime?
www.fool.com - November 18 at 7:07 PM
[$$] New Valeant chief nurses $1.3m paper loss on shares[$$] New Valeant chief nurses $1.3m paper loss on shares
www.ft.com - November 13 at 11:23 AM
Ackman: Valeant Can Sell Non-Core Assets to Reduce DebtAckman: Valeant Can Sell Non-Core Assets to Reduce Debt
www.thestreet.com - November 10 at 7:29 PM
Selling Salix Could Be the Most "Valeant" Move EverSelling Salix Could Be the Most "Valeant" Move Ever
www.fool.com - November 9 at 7:34 PM
Valeant Pharmaceuticals Just Delivered a Trifecta of Bad News in Its Q3 ReportValeant Pharmaceuticals Just Delivered a Trifecta of Bad News in Its Q3 Report
www.fool.com - November 9 at 10:15 AM
Valeants Possible Fire Sale Looks Worse Than EverValeant's Possible Fire Sale Looks Worse Than Ever
www.bloomberg.com - November 8 at 7:24 PM
[$$] Valeant shares fall after sales and earnings targets cut[$$] Valeant shares fall after sales and earnings targets cut
www.ft.com - November 8 at 11:22 AM
Analysts Remain Wary Ahead of Valeant EarningsAnalysts Remain Wary Ahead of Valeant Earnings
www.thestreet.com - November 7 at 8:23 PM
Valeant earnings: Expect an update on plans to sell SalixValeant earnings: Expect an update on plans to sell Salix
www.marketwatch.com - November 7 at 8:23 PM
[$$] Valeant: I love you, you pay my rent[$$] Valeant: I love you, you pay my rent
www.ft.com - November 2 at 7:51 PM
Negative Analyst Commentary Pushes Valeant Pharmaceuticals Intl. Inc. Lower by 11%Negative Analyst Commentary Pushes Valeant Pharmaceuticals Intl. Inc. Lower by 11%
www.fool.com - November 2 at 7:51 PM
Valeant: A Good Strategic Move?Valeant: A Good Strategic Move?
blogs.barrons.com - November 2 at 7:51 PM
Valeant: Selling Salix a Warning of Trouble to Come?Valeant: Selling Salix a Warning of Trouble to Come?
blogs.barrons.com - November 2 at 11:02 AM
Hold the Valeant ApplauseHold the Valeant Applause
www.bloomberg.com - November 2 at 11:02 AM
Valeant gets new approval for legacy Salix drugValeant gets new approval for legacy Salix drug
www.bizjournals.com - July 20 at 1:50 PM
Valeants Drug Approvals May Save the DayValeant's Drug Approvals May Save the Day
www.thestreet.com - July 20 at 12:30 PM
How Much Is Valeant Pharmaceuticals Really Worth?How Much Is Valeant Pharmaceuticals Really Worth?
www.fool.com - June 17 at 2:41 PM
Details of kickbacks and fraud emerge in Valeants Salix unit settlementDetails of kickbacks and fraud emerge in Valeant's Salix unit settlement
www.bizjournals.com - June 10 at 11:55 AM

SEC Filings

Salix Pharmaceuticals (NASDAQ:SLXP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Salix Pharmaceuticals (NASDAQ:SLXP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Salix Pharmaceuticals (NASDAQ SLXP) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.